Hummingbird Bioscience, an innovative systems-biology enabled biotechnology company, has today announced a multi-target collaboration to co-discover novel antibody therapeutics with Amgen. This partnership brings together Hummingbird’s proprietary drug discovery platform with Amgen’s disease expertise and drug development capabilities.

Under the terms of the agreement, Amgen will provide Hummingbird with two of its proprietary targets and allows for further expansion of up to 10 additional targets over a 6-year period upon which Hummingbird will apply its proprietary Rational Antibody Discovery platform to create novel therapeutic antibodies. Amgen has an exclusive option to license rights to the resulting antibodies from each project. Hummingbird will receive upfront and research payments and, upon entry into a license agreement, is also eligible to receive downstream clinical and commercial milestone payments of up to $100 million per program plus royalties. Additional financial details are not being disclosed.

Hummingbird’s Rational Antibody Discovery platform is a highly innovative systems immunology and computational structural biology approach that enables precise targeting of epitopes and mechanism of action on a target protein, unlocking targets that were previously challenging to develop drugs against, such as GPCRs and ion channels. In this collaboration, the Hummingbird platform will be deployed against multiple high-value drug targets, selected by Amgen, to develop antibodies that will deliver potent therapeutic benefit to patients with limited treatment options.

Piers Ingram, Hummingbird CEO said, “Hummingbird is excited to be working with Amgen on some of the most challenging and high-value targets in drug development. Hummingbird’s Rational Antibody Discovery Platform offers a unique opportunity to leverage the cutting-edge science and domain expertise of Amgen to deliver benefit to targeted patient groups in multiple disease indications.”

About Hummingbird Bioscience

Hummingbird Bioscience is an innovative biotech company, with facilities in Singapore, South San Francisco, California and Houston, Texas, focused on applying advances in systems biology to rapidly develop successful cancer therapeutics for patients with limited treatment options. Recognition of the importance of both tumor evolution and evasion of immune response as key “hallmarks of cancer” has provided a wide class of new drug targets. Building on these insights, Hummingbird is applying integrative genomics and proteomics to develop a comprehensive framework to systematically address the barriers to an effective anti-tumor response in every patient. Using its Rational Antibody Discovery Platform, a proprietary systems immunology and computational structural biology approach that enables precise targeting of epitopes and mechanisms of action on cancer-associated proteins, Hummingbird Bioscience has developed a pipeline of highly promising first and best-in-class oncology and immuno-oncology drugs. Within its pipeline, HMBD-001 (anti-HER3 antibody) and HMBD-002 (anti-VISTA antibody) are anticipated to start clinical trials in 2020. For more information on Hummingbird Bioscience visit: www.hummingbirdbioscience.com

Hummingbird Bioscience may be contacted at contact@hummingbirdbio.com or +65 6266 2617